Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

56 results about "Combination Product" patented technology

A product comprised of two or more regulated components, i.e., drug and device, biologic and device, that are physically, chemically, or otherwise combined or mixed and produced as a single entity; or two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products; or a drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or any investigational drug, device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect.

Nucleic acid combination product, kit and method for detecting various respiratory tract pathogenic bacteria

The invention discloses a nucleic acid combination product, a kit and a method for detecting various respiratory tract pathogenic bacteria. The nucleic acid combination product comprises a primer pair and a probe, wherein the sequences of the primer pair and the probe are respectively shown as SEQ ID NO: 1-SEQ ID NO: 24. The nucleic acid combination product realizes synchronous detection of various pathogens through a one-tube eight-color fluorescent PCR, freeze-drying and ultrasonic direct diffusion method technology, significantly reduces experimental operation steps, shortens detection time, reduces the complexity of result interpretation, and has strong anti-interference capability and high sensitivity.
Owner:SANSURE BIOTECH INC

Nucleic acid combination product for detecting multiple respiratory pathogens, kit containing nucleic acid combination product and method

The invention discloses a nucleic acid combination product for detecting various respiratory pathogens, a kit containing the nucleic acid combination product and a method. The nucleic acid combination product comprises a primer pair and a probe, wherein the nucleotide sequences of the primer pair and the probe are respectively shown as SEQ ID NO: 1-21. According to the nucleic acid combination product, on the technical basis of Taqman fluorescent quantification, seven targets can be detected by one tube, so that the time and energy of operators are greatly shortened, and the nucleic acid combination product is convenient and rapid, is not easy to make mistakes, and is simpler and easier to understand in result interpretation.
Owner:SANSURE BIOTECH INC

Otic drug delivery system and methods

Disclosed herein are drug delivery devices including catheter assemblies, infusion systems, pre-filled syringes, methods of use, combination products, kits of parts, and drug products with parts lists for independent sourcing, for use in the otic administration of a drug product to a subject in need thereof.
Owner:REGENERON PHARMACEUTICALS INC

Anti-CD40 antibodies and their uses

This invention relates to anti-CD40 antibodies or antigen-binding fragments thereof that specifically recognize and weakly activate CD40 molecules in humans, cynomolgus monkeys, and mice, as well as immunoconjugates, pharmaceutical compositions, and combination products comprising said anti-CD40 antibodies or antigen-binding fragments thereof. The invention also relates to nucleic acids encoding said anti-CD40 antibodies or antigen-binding fragments thereof and host cells comprising said nucleic acids, and methods for preparing said anti-CD40 antibodies or antigen-binding fragments thereof. Furthermore, the invention relates to the use of said anti-CD40 antibodies or antigen-binding fragments thereof in the prevention or treatment of tumors or infectious diseases in subjects.
Owner:ANHUI RUBIOX VISION BIOTECH +1

Primer probe combination product for respiratory tract infection detection

The invention relates to the technical field of biology, in particular to a primer probe combination product for respiratory tract infection detection. A plurality of specific primers and self-quenching probes are integrated in a single reaction system; simultaneous, rapid and rapid detection on 15 respiratory pathogens (including influenza A virus, influenza B virus, respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, mycoplasma pneumoniae, parainfluenza virus, rhinovirus, enterovirus, coronavirus, adenovirus, metapneumovirus, bordetella pertussis, bocavirus, chlamydia pneumoniae and chlamydia psittaci) is realized. The detection is accurate.
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL +2

Smoking system, device kit, consumables, combination products, and method for obtaining end-user sensation and end-user anticipation.

ActiveJP7884112B2MedicineEngineering
To provide a smoking system that when a flavor generation article is inserted into a chamber, allows a user to easily feel arrival at an end of the chamber and to easily foresee that it will arrive at the end of the chamber.SOLUTION: When a resistance value when a flavor generation article is inserted into a storage part and a tip of the flavor generation article arrives at an end of the storage part, is insertion force A, and a ratio of a rear-half average resistance force to a front-half average resistance force is a first resistance ratio B, a smoking system satisfies A≤4.00 N and B>1.0, where the rear-half average resistance value is an average of resistance values from a midpoint between a prescribed position on an insertion end side of the storage part and an end of the storage part to the end of the storage part. and the front-half average resistance force is an average of resistance values from the prescribed position to a midpoint between the prescribed position and the end of the storage part.SELECTED DRAWING: Figure 16
Owner:JAPAN TOBACCO INC

Nucleic acid combination product, kit and method for detecting a plurality of respiratory pathogens

The application discloses a nucleic acid combination product, a kit and a method for detecting multiple respiratory tract pathogenic bacteria. The nucleic acid combination product comprises a primer pair and a probe, wherein the sequences of the primer pair are respectively shown as SEQ ID NO:1-SEQ ID NO:24. The nucleic acid combination product realizes the synchronous detection of multiple pathogenic bacteria through one-tube eight-color fluorescence PCR, freeze-drying and ultrasonic direct extension technology, significantly reduces the experimental operation steps, shortens the detection time, reduces the complexity of result interpretation, and has strong anti-interference ability and high sensitivity.
Owner:SANSURE BIOTECH INC

Combination product for relieving the symptoms associated with upper respiratory tract infections

The present invention relates to a combination product comprising, as active substances, at least erysimum, propolis, zinc, ribwort plantain, and marshmallow. The invention also relates to the use of a combination product as defined above for treating the symptoms associated with upper respiratory tract infections. Finally, the invention relates to the use of a combination product as defined above for treating the symptoms associated with throat infections and irritation.
Owner:URGO RECH INNOVATION & DEVEMENT

Methods for evaluating the effectiveness of aerosols for pulmonary drug delivery using inhaler devices, oral inhalation and / or nasal medications, and drug / device combination products.

PendingJP2026521839AInhaled drugEfficacy
The present invention relates to a method for evaluating the effectiveness of an aerosol (3) for pulmonary drug delivery, as well as inhaler devices (2, 2a, 2b, 2c, 2d), orally inhaled drugs (1), and drug / device combination products (7). [Solution] An inhaler device (2, 2a, 2b, 2c, 2d) can generate an aerosol (3), which contains aerosol particles (30) containing an orally inhaled drug (1). The method includes the steps of providing a computational lung model (Lmod) and a computational particle transport and deposition model (Pmod), calculating the spatial particle deposition distribution (Ddist) of discrete particles (30') based on a determined aerosol value (Aval) of an aerosol parameter (Apar), calculating the efficacy value (Eval) of an efficacy parameter (Epar) based on the spatial particle deposition distribution (Ddist), and using the efficacy value (Eval) to automatically evaluate the efficacy of the aerosol (3) for lung drug delivery.
Owner:EBENBUILD GMBH

Nucleic acid combination, kit for identification of mycobacteria and use thereof

This application belongs to the field of molecular biology technology, specifically relating to nucleic acid combo products, kits for mycobacterial identification, and their applications. This application provides a nucleic acid combo product for mycobacterial detection, comprising one or more primer pairs with nucleotide sequences as shown in SEQ ID NO.1 to SEQ ID NO.244. This specific primer combination can simultaneously detect multiple mycobacteria and distinguish them down to the subspecies level. Through highly specific primer design, this nucleic acid combo product can achieve accurate identification of common clinical mycobacteria (including complex groups, species, and subspecies levels), with a detection sensitivity of 50-100 CFU / mL, significantly superior to the detection performance of existing technologies. Furthermore, the nucleic acid combo product of this application can not only identify the species of mycobacteria but also simultaneously detect drug resistance gene mutations, providing important evidence for the selection of clinical treatment regimens.
Owner:广州市胸科医院 +1

New use

PCT designated stageWO2026026944A1Organic active ingredientsRespiratory disorderInterstitial pneumoniasPharmaceutical drug
The present disclosure relates to a new use, and mainly relates to the use of an FAK inhibitor, such as IN10018, in the preparation of a drug for treating or preventing interstitial pneumonia, a method for treating or preventing interstitial pneumonia by means of administering a therapeutically effective amount of the FAK inhibitor, such as IN10018, and a pharmaceutical combination product, kit and pharmaceutical composition containing the FAK inhibitor, such as IN 10018, for treating or preventing interstitial pneumonia.
Owner:INXMED (NANJING) CO LTD

Nucleic acid combination product, PCR premix, method and kit for identifying respiratory tract pathogenic bacteria

The invention relates to the technical field of biological detection, in particular to a nucleic acid combination product, a PCR premix, a method and a kit for identifying respiratory tract pathogenic bacteria. The nucleic acid combination product comprises a primer pair as shown in SEQ ID NO: 1 to SEQ ID NO: 21 and a probe. The invention provides a nucleic acid detection product for detecting klebsiella pneumoniae, streptococcus pneumoniae, haemophilus influenzae, pseudomonas aeruginosa, acinetobacter baumannii, staphylococcus aureus and moraxella catarrhalis, and the nucleic acid detection product can be used for performing amplification detection on conserved fragments of target pathogens in the same PCR reaction system, and is efficient and low in cost. Moreover, the anti-interference capability is strong, and the sensitivity is high.
Owner:SANSURE BIOTECH INC

Compositions containing propafenone and mexiletine and their use

A pharmaceutical composition in a fixed-dose combination is described, comprising: a) a dofetilide component; and b) a mexiletine component; wherein the dofetilide component and the mexiletine component are physically separated from each other, and a method for treating or preventing atrial fibrillation or related symptoms in a subject by administering such pharmaceutical composition to a subject in need, and a method for preparing such a fixed-dose combination product.
Owner:FB HRS LLC

Combination product for the treatment of leishmaniasis

PCT designated stageWO2026047114A1Protozoa antigen ingredientsAntiparasitic agentsLeishmaniasisGenus: Leishmania
The present application provides a combination product for the treatment and / or prevention of infections caused by parasites of the genus Leishmania.
Owner:BIOTECHNOLOGY ASSETS SA +1

Nucleic acid panel, pcr master mix, kit, and method for identifying respiratory pathogens

The application relates to the technical field of molecular biology detection, in particular to a nucleic acid combination product for identifying respiratory tract pathogens, a PCR premix, a kit and a method. The nucleic acid combination product comprises primer pairs and probes shown in SEQ ID NO: 1 to SEQ ID NO: 21. The primer pairs and the probes can be mixed with other reagents required by PCR, and then freeze-dried to prepare a freeze-dried ball. The freeze-dried ball is smooth and round in surface, and after a nucleic acid sample liquid to be detected is directly dropped into a PCR reaction tube containing the freeze-dried ball, machine detection can be carried out. The freeze-dried ball is not only beneficial to storage and transportation, but also convenient to operate. In particular, the effect of joint detection of target pathogens is good, and the detection sensitivity is also improved.
Owner:SANSURE BIOTECH INC

Combination product of a BCL-2 / BCL-XL inhibitor and a chemotherapeutic agent and use thereof in the prevention and / or treatment of diseases

The present invention relates to a combination product comprising a Bcl-2 / Bcl-xL inhibitor and a chemotherapeutic agent, in particular a Bcl-2 / Bcl-xL inhibitor of formula I-A and homoharringtonine or an active derivative thereof, in free or pharmaceutically acceptable salt or solvate form. The invention also relates to the use of the aforementioned combination for the preparation of a medicament for the prevention and / or treatment of cancer, in particular of hematological malignancies, and to a method for the prevention and / or treatment of cancer, in particular of hematological malignancies, using the aforementioned combination.
Owner:ASCENTAGE PHARMA SUZHOU CO LTD +1

Liposomal formulation and use in a combination product as an Anti-tumour therapy

A pharmaceutical combination product including:a liposomal formulation consisting of one or more liposomes each encapsulating a bacterial lipopolysaccharide (LPS) as a single active ingredient; andat least one anti-tumor compound chosen from the group consisting of: a therapeutic antibody, a chemotherapy agent, and an immunotherapy agent.Methods for treating a tumor comprising administering to a patient having said tumor an effective amount of said pharmaceutical combination product.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +4

Nucleic acid combination product, PCR (Polymerase Chain Reaction) premixed solution, kit and method for identifying respiratory pathogens

The invention relates to the technical field of molecular biological detection, in particular to a nucleic acid combination product, a PCR premixed solution, a kit and a method for identifying respiratory pathogens. The nucleic acid combination product comprises a primer pair as shown in SEQ ID NO: 1 to SEQ ID NO: 21 and a probe. The primer pair and the probe combination can be mixed with other reagents required by PCR and then freeze-dried to prepare freeze-dried balls, the surfaces of the freeze-dried balls are smooth and round, nucleic acid sample liquid to be detected can be directly dropwise added into a PCR reaction tube filled with the freeze-dried balls and then can be detected on a machine, storage and transportation are facilitated, operation is convenient and fast, the combined detection effect of target pathogens is especially good, and the detection efficiency is high. And the detection sensitivity is also improved.
Owner:SANSURE BIOTECH INC

Composition for local administration of tumor, medical and mechanical combined product and application of composition and medical and mechanical combined product

PendingCN121987551AOrganic active ingredientsGuide needlesInitial treatmentRegimen
The invention relates to a composition for tumor local injection, a medical and mechanical combined product and application of the composition in preparation of a medicine for tumor local injection administration. The composition comprises an antitumor drug component, an immunologic adjuvant and a drug carrier. By means of the jet flow microneedle delivery device which is specially designed, tumor local drug delivery of anti-tumor drugs can be achieved, and the problem that the maximum drug dosage and the treatment effect are limited due to system toxicity in traditional intravenous drug delivery is solved. The high-concentration local administration of the composition provided by the invention not only improves the local treatment effect of tumors, but also can effectively generate tumor antigens. The tumor antigen generated in situ can be matched with an immunologic adjuvant in the composition to generate tumor specific immune cells on the premise that the immune system of a patient is not damaged due to the toxicity of a drug system, so that the immune response of the local part and the whole body of the patient to tumors is improved. Besides, in the subsequent treatment course after the initial treatment, only the composition of the immunologic adjuvant and the tumor specific polypeptide or the immunologic adjuvant can be given to maintain and enhance the established tumor specific immune response, and accumulated toxicity caused by repeated use of chemotherapeutic drugs is avoided.
Owner:NOMEDEL USA LLC +1

Nucleic acid panel, pcr master mix, kit and method for identifying respiratory pathogens

The application relates to the technical field of molecular biology detection, in particular to a nucleic acid combination product for identifying respiratory tract pathogens, a PCR premix, a kit and a method. The nucleic acid combination product comprises a primer pair and a probe with sequences shown in SEQ ID NO: 1 to SEQ ID NO: 21. The nucleic acid combination product comprises a primer pair and a probe for detecting target pathogens, and in the process of detecting multiple targets based on the same reaction system, cross-reactions can be avoided, and the interference of drugs can also be avoided. In addition, the nucleic acid combination product is suitable for preparing a freeze-dried reagent, and through the selection of a freeze-drying protective agent component, primer probe damage can be avoided, and the compatibility of multiple components can be improved.
Owner:SANSURE BIOTECH INC

Liquefied combination product of viscous biological sample, nucleic acid detection kit and application thereof

ActiveCN121406752AMicrobiological testing/measurementL-acetylcysteineMorpholine
The invention provides a liquefaction combination product of a viscous biological sample, a nucleic acid detection kit and application of the liquefaction combination product. The liquefied combination product of the viscous biological sample comprises a first component and a second component, the first component is prepared from the following components: 10 mmol / L to 100 mmol / L of acetylcysteine, 5 mmol / L to 50 mmol / L of guaifenesin and 2 mmol / L to 20 mmol / L of 2-morpholine ethanesulfonic acid; the second component comprises a strong alkali solution, and the concentration of strong alkali in the strong alkali solution is 5 mol / L-20 mol / L. Specific acetylcysteine, guaifenesin and 2-morpholinoethanesulfonic acid are matched for use according to a specific proportioning relation, so that a viscous biological sample is quickly and sufficiently liquefied at room temperature, and the repeatability is relatively high. And the sample treated by the first component and the second component of the liquefied combined product prevents the strong acidity in the first component from interfering with the subsequent nucleic acid detection result.
Owner:SANSURE BIOTECH INC

CAR peptide for improved coronavirus survival

A conjugate for treating an individual suffering from a disease, wherein the conjugate is comprised of: a targeting peptide comprising a sequence substantially identical to CAR, or a variant thereof; and at least one therapeutic molecule and methods for making and administering same. Also disclosed is a combination product for use in the treatment of a disease, wherein the combination product comprises: (a) a targeting peptide comprising a sequence substantially identical to CAR, or a variant thereof; (b) a liposome, wherein the targeting peptide is encapsulated within the liposome; and (c) an effective amount of an anti-inflammatory agent and methods for making and administering same.
Owner:VASCULAR BIOSCI

Nucleic acid combination product, kit for detecting mycobacterium tuberculosis complex and drug resistance gene mutation and application thereof

This application belongs to the field of molecular biology technology, specifically relating to nucleic acid combinatorial products, kits for identifying Mycobacterium tuberculosis complexes and detecting drug resistance gene mutations, and their applications. This application provides a nucleic acid combinatorial product for tNGS detection of Mycobacterium tuberculosis complexes and related drug resistance genes, comprising at least one pair of primers selected from the nucleotide sequences shown in SEQ ID NO.1 to SEQ ID NO.344. Through optimized primer design, this product significantly improves multiplex PCR amplification efficiency and detection sensitivity. Compared to other NGS technologies such as single-molecule sequencing, this product significantly reduces detection costs while ensuring comprehensive detection, and can complete the entire analysis process from sample processing to result reporting within 24 hours. Furthermore, this nucleic acid combinatorial product also has species identification capabilities, accurately distinguishing Mycobacterium tuberculosis complexes and their species and variant levels, thereby achieving synergistic improvements in detection breadth, cost, timeliness, and identification accuracy.
Owner:广州市胸科医院 +1

A pharmaceutical combination product for enhancing the therapeutic effect of nanomedicines

The present application relates to a kind of drug combination products for enhancing the therapeutic effect of nanomedicine, belong to nanomedicine technical field.The drug combination product includes following (1), (2) and (3): (1) stimulus-responsive nanomedicine;(2) mononuclear phagocyte system blocker;(3) exogenous reducing substance.The drug combination product provided by the present application carries out the regulation in time sequence to the in vivo delivery and release process of nanomedicine by "first block then loose" delivery strategy, realizes the effective accumulation and intelligent release of nanomedicine in target tissue, to improve the therapeutic effect.
Owner:SHENYANG PHARMA UNIV

Immunotherapeutic vaccine and antibody combination therapy

The present invention relates to a combination product, composition(s) and kit of parts comprising at least (i) a therapeutic vaccine and (ii) one or more immune checkpoint modulator(s). The present invention also concerns a method for treating a proliferative or an infectious disease as well as a method for eliciting or stimulating and / or re-orienting an immune response, wherein said methods comprise administering to a subject in need thereof said combination product or said composition(s).
Owner:TRANSGENE SA